Phase 2 study evaluating an investigational weekly oral combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir to resume with lower dose of islatravir
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
This launch builds upon Hikma’s leading position as one of the largest US providers of nasally administered medicines used for treating seasonal allergies and advances its objective of growing its specialty business in the US
75 inter-disciplinary, multi-institutional grants would be supported for high-risk, ambitious research ideas, milestones-driven collaborative research in all domain areas of the biotech sector
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
The compendium was released by Suman Bery, Vice-Chairman, NITI Aayog and Dr. Munjpara Mahendrabhai Kalubhai, Minister of State for Ayush and WCD.
Subscribe To Our Newsletter & Stay Updated
